OR-RADISYS
17.12.2020 14:02:14 CET | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today announced that ContactMakers , a contact center telephony solutions and customer care provider, has selected Radisys Engage Media Server as the foundation for its VOIP Communication ContactSuite platform as it moves the solution to the cloud. The Engage Media Server’s extensive flexible capabilities enable ContactMakers to focus its resources to add unique applications, enhanced user experience and custom capabilities for its unique customer interaction suite, rather than on the communications infrastructure. ContactMakers will be able to use the media server to address specific customer requirements more quickly, while reducing costs and complexity by utilizing a common media processing platform for advanced voice, video, media analytics, and other capabilities for its customer offerings.
Highlights
- Customer contact is always critical to business. Despite the evolution and expansion of communication channels including the internet, text messaging and social media, telecommunications access solutions like business VOIP, mobile and landlines continue to anchor a high volume of interactions including the most critical customer care interactions.
- With today’s fluid workforce, dynamic global conditions and a growing trend toward remote customer interactions, having a reliable media foundation for real-time voice and video sessions is more critical than ever. To meet this challenge, businesses need a contact center solution that enables them to bring new, scalable and elastic services online more quickly and that can be adapted to changing market conditions more easily than existing off-the-shelf Customer Communication-as-a-Service (CCaaS) products.
- ContactMakers is undertaking a telco-to-the-cloud migration of its proprietary communications application and interaction platform which it has built and optimized for clients’ customer communication requirements for more than 15 years. Leveraging Radisys Engage Media Server’s cloud-native platform, ContactMakers will be able to lower the cost of migration, deliver greater flexibility, and provide optimal resource utilization.
- ContactMakers will use the Engage Media Server to deliver telco-grade reliability, video, speech processing, biometrics, and high-quality voice capabilities as the anchor for its service platform.
- Radisys Engage Media Server is the industry’s leading real-time media processing platform that provides voice, video, and AI-based media, delivering a complete solution set for developers, CCaaS providers and Communications Service Providers (CSP) to create a wholistic digital customer engagement experience.
-
Customer Care, Unified Communications (UC) and CCaaS providers, including OEM and managed service providers alike, depend on Radisys for high quality, cloud-based media processing that can meet dynamic customer, market, and employee conditions, while providing a future-proof, market leading solutions including:
- Cloud scalability for broader market reach for digital experience applications and services at attractive price points
- Highest quality voice and video processing
- Support for VOIP, mobile and landline customer and employee connections
- Telco-grade reliability to ensure “always on” communications
“We have had a long relationship with Radisys to deliver high-quality communication services that our customers expect. Now, with Radisys’ help, we are able to seamlessly transition to a software environment that can run in our private data center or in the cloud,” said Denise Konings, CEO, ContactMakers. “The combination of Radisys technology, its consultative expertise in the rapidly evolving communications and mobile technology domain, and its world-class global support make Radisys not only a technology supplier, but our key partner in delivering high quality, engaging, customer interactions.”
“Reliable, scalable and cloud-based media processing is the foundation for delivering memorable customer interactions,” said Shankar Krishnamurthy, Radisys’ Senior Director, Business Development. “Engage Media Server is enabling ContactMakers to migrate its services to the cloud to better manage communication workflows, improve the user experience, and track critical customer and employee key performance indicators. It also allows ContactMakers to continue to focus its specialized resources and development budget on service applications.”
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .
About ContactMakers
ContactMakers facilitates and realizes top-level telephony for companies that go for quality in customer service. Superior communication technology in the cloud combined with people skills, passion and drive. ContactMakers inspires and challenges you to make every customer contact moment the best that it can be. Together we'll optimize every phase of the customer experience cycle. Visit www.contactmakers.nl for more information.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005338/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
